Type II collagen antibody response is enriched in the synovial fluid of rheumatoid joints and directed to the same major epitopes as in collagen induced arthritis in primates and mice by Lindh, Ingrid et al.
Lindh et al. Arthritis Research & Therapy 2014, 16:R143
http://arthritis-research.com/content/16/4/R143RESEARCH ARTICLE Open AccessType II collagen antibody response is enriched in
the synovial fluid of rheumatoid joints and
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Michel Vierboom3, Bert 't Hart3, Vivianne Malmström2 and Rikard Holmdahl1*Abstract
Introduction: Antibodies towards type II collagen (CII) are detected in patients with rheumatoid arthritis (RA) and in
non-human primates and rodents with collagen induced arthritis (CIA). We have previously shown that antibodies
specific for several CII-epitopes are pathogenic using monoclonal antibodies from arthritic mice, although the role of
different anti-CII epitopes has not been investigated in detail in other species. We therefore performed an inter-species
comparative study of the autoantibody response to CII in patients with RA versus monkeys and mice with CIA.
Methods: Analysis of the full epitope repertoire along the disease course of CIA was performed using a library of CII
triple-helical peptides. The antibody responses to the major CII epitopes were analyzed in sera and synovial fluid from
RA patients, and in sera from rhesus monkeys (Macaca mulatta), common marmosets (Callithrix jacchus) and mice.
Results: Many CII epitopes including the major C1, U1, and J1 were associated with established CIA and arginine
residues played an important role in the anti-CII antibody interactions. The major epitopes were also recognized in RA
patients, both in sera and even more pronounced in synovial fluid: 77% of the patients had antibodies to the U1
epitope. The anti-CII immune response was not restricted to the anti-citrulline protein antibodies (ACPA) positive RA
group.
Conclusion: CII conformational dependent antibody responses are common in RA and are likely to originate from
rheumatoid joints but did not show a correlation with ACPA response. Importantly, the fine specificity of the anti-CII
response is similar with CIA in monkeys and rodents where the recognized epitopes are conserved and have a major
pathogenic role. Thus, anti-CII antibodies may both contribute to, as well as be the consequence of, local joint
inflammation.Introduction
Rheumatoid arthritis (RA) is an autoimmune, chronic
inflammatory disorder affecting peripheral joints. RA is
a complex disorder believed to consist of different pa-
thogenetic mechanisms that may lead to common final
pathways and shared clinical signs and symptoms. Re-
cent progress has strengthened the view that a patho-
genic process leading to RA starts many years before the* Correspondence: Rikard.Holmdahl@ki.se
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factors) combined with a raised systemic inflammatory re-
sponse. Many years later the joints are affected. During
the pre-RA period the autoantibody responses, including
ACPA, is increased in titers and spreads in epitope specifi-
city [1] and that antibodies to cartilage can be measured
around clinical onset [2-4], where one of the autoantibody
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sponse, ranging from a few percent up to 50% [3,4]. Also
unclear is whether the low titers can be of pathogenic or
regulatory relevance. These variable results are probably
due to technical artifacts due to the usage of solid-phase
assays with crudely purified matrix protein.
Immunization of CII in animals gives rise to significant
titers of autoantibodies to CII. Three CII-specific mono-
clonal antibodies (CII-C1, UL-1, and M2139) have been
raised and characterized in detail by the molecular inter-
action with their target molecule [5-8], binding in vivo
[9], and their pathogenic and regulatory importance
[10]. It would therefore be of value to directly compare
human antibody specificities with the specificity of auto-
antibodies in animals and also to develop assays that are
not dependent on collagen prepared from tissue com-
plexed with not very well defined matrix molecules, and
instead use synthetic and recombinant triple-helical CII
peptides containing identified epitopes known to be ex-
posed and recognized by antibodies in vivo. The purpose
of this study was thus to investigate the epitope reper-
toire of the major CII epitopes and to analyze these not
only in RA but also in a comparative way in other spe-
cies; that is, in monkeys and mice with collagen-induced
arthritis (CIA).
Materials and methods
Rheumatoid arthritis patients and healthy subjects
Serum and synovial fluid (SF) samples were collected from
a previously described patient cohort [11] with established
RA (290 patients, mean age 55, age range 21 to 86, 82% fe-
male) according to the American College of Rheumatology
criteria [12]. For serum analysis of the C1 epitope, an
additional 124 patients were included, giving a total of 414
patients (mean age 59, age range 21 to 100, 80% female).
All patients attended the Rheumatology Clinic at the
Karolinska University Hospital, Sweden, and were in-
cluded based on a clinical need for withdrawing SF from
knee effusions. Serum sampling was performed in parallel.
One hundred serum samples from healthy subjects (mean
age 54, range 24 to 82, 81% female) were also analyzed
and served as controls in this study. The ethical review
board of the Karolinska University Hospital (Regionala
Etikprövningsnämnden Stockholm) approved this study,
and all subjects gave informed consent.
Nonhuman primates and mice
The Biomedical Primate Research Centre in Rijswijk, the
Netherlands supplied sera from both rhesus monkeys
(Macaca mulatta) and common marmosets (Callithrix
jacchus). The monkeys were at adult age, rhesus mon-
keys >4 years and common marmosets >1.5 years, when
the experiments were performed. In accordance with the
Dutch law on animal experimentation, all study protocolsin which these animals took part were reviewed and ap-
proved by the Institute’s Ethics Committee (Biomedical
Primate Research Centre) before the experiments started
(application numbers 589, 605, 613/618, 633, 484, 542,
581). The B10.Q/rhd mice originated from Professor Jan
Klein, Tübingen, Germany, whereas the BALB/cJ mice
originated from Jackson Laboratories (Bar Harbor, ME,
USA). The parental inbred strain as well as the B10.Q ×
(BALB/c × B10.Q) N2 strain were bred in the animal facil-
ity of the Institute of Medical Inflammation Research at
Lund University, Sweden. The animals were between 8 and
12 weeks old at the start of the experiments. Stockholm
norra försöksdjursetiska kommiten, Stockholm, Sweden
(permission number N66/10, N169/10) approved the
experiments.Induction and evaluation of CIA in rhesus monkeys and
common marmosets
Rhesus monkeys were immunized with chicken-derived
CII (MD Biosciences, Zürich, Switzerland) and common
marmoset monkeys were immunized with either chicken
or bovine-derived CII (MD Biosciences), which were
dissolved in 0.1 M acetic acid to a final concentration of
10 mg/ml (for rhesus monkeys) and 5 mg/ml (for com-
mon marmosets) and mixed with an equal volume of
complete Freund’s adjuvant (Difco, Detroit, MI, USA).
CIA was induced by injection of 1 ml (rhesus monkeys)
and 0.4 ml emulsion (common marmosets) into the dor-
sal skin, distributed over 10 spots (rhesus monkeys) and
four spots (common marmosets). Clinical signs of arth-
ritis were recorded daily by monitoring of behavioral
changes or pain. Twice per week the monkeys underwent
a complete physical inspection of all the joints for redness
and/or swelling using the integrated discomforted scoring
scheme [13]. Late-stage sera were collected from all mon-
keys and used for CII-specific analysis.Induction and evaluation of CIA in mice
Rat CII was prepared from the SWARM chondrosarcoma
by pepsin digestion as described previously [14,15]. For in-
duction of chronic arthritis, B10.Q × (BALB/c × B10.Q)
N2 mice (n = 10) were immunized with 100 μg rat CII in
0.1 M acetic acid, emulsified in incomplete Freund’s adju-
vant (Difco). For induction of acute arthritis, B10.Q mice
(n = 10) were immunized similarly except for the use of
complete Freund’s adjuvant (Difco). Both strains were
boosted at day 35 with 50 μg rat CII in incomplete
Freund’s adjuvant. Clinical scoring of animals was done
blindly up to 80 days for acute arthritis and up to 210 days
for chronic arthritis using a macroscopic scoring system: 1
point was given for each swollen or red toe or joint and 5
points for a swollen ankle, adding up to a maximum score
of 60 points per mouse.
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Rheumatoid arthritis patients
The synthesis of human triple-helical CII peptides has been
described in detail elsewhere [16]. For antibody measure-
ments, enzyme-linked immunosorbent assay plates
(NUNC, Roskilde, Denmark) were coated with human CII
peptides C1, U1, and J1 (5 μg/ml) at 4°C overnight. After
blocking the plates, paired serum and SF samples (diluted
1:100 in radioimmunoassay buffer +10% fetal calf serum)
were added followed by incubation for 2 hours at room
temperature. Horseradish peroxidase-conjugated goat anti-
human IgG (Jackson Immuno Research Laboratories, West
Grove, PA, USA) was then added, and interaction with
bound antibodies was detected using the chromogenic
substrate TMB (Sigma-Aldrich St. Louis, MO, USA). Plates
were read at 450 nm with a reference of 650 nm. A stand-
ard curve from a positive serum to specific antigen was
included on each plate and was further used to translate
optical density values to arbitrary units. The cutoff was de-
termined as the mean ± three standard deviations using
the control cohort of 100 healthy individuals. To be able
to include all analyzed individuals in the graphs, negative
responders were given a value of 0.1, which is below the
detection limit for positivity. The total IgG concentra-
tion (g/l) was determined at the Clinical Immunology
Laboratory, Karolinska Hospital, Solna, using commercial
radial immune-diffusion assays (Dade-Behring, Marburg,
Germany) and rate nephelometry (IMMAGE Immuno-
chemistry System; Beckman Coulter, Fullerton, CA, USA).
The assays were calibrated against the international stand-
ard CRM470. The paired SF samples were normalized
based on the values for total IgG.
Nonhuman primates
Enzyme-linked immunosorbent assay plates (NUNC)
were coated with rat CII (10 μg/ml) and the synthetic
CII peptides C1, U1, and J1 (5 μg/ml) at 4°C overnight.
After blocking the plates, serum samples (diluted
1:400) from arthritic CIA monkeys were added and
incubated for 2 hours in room temperature. Alkaline
phosphatase-conjugated goat (fab)2 anti-monkey IgG
(Invitrogen, Carlsbad, CA, USA) was then added to the
bound antibodies, which were detected with polynitrophe-
nylphosphate diluted in Tris buffer (Sigma Aldrich, St.
Loius, MO, USA). Absorbance at 405 nm was measured
with a Synergy 2 plate reader (BioTek Instruments). The
cutoff value for the assay was calculated as the mean ab-
sorbance value of the antibody response to the CII epi-
topes from naive monkeys ± three standard deviations
(calculated to 0.11). All absorbance values below this cut-
off value were considered negative. The serum dilution re-
quired for each primate to reach the cutoff absorbance
value was calculated. All animals with antibody titers
below the detection limit were assigned a value of 1.Statistical analysis
One-way analysis of variance (Kruskal–Wallis test) fol-
lowed by Dunn’s multiple comparison tests were used to
analyze the differences between RA and healthy control
groups. A paired t test (Wilcoxon signed-rank test) was
used for comparison between serum and SF antibody
levels. P < 0.05 was considered statistically significant.
Quantitative data are expressed as the mean ± standard
error of the mean, and significance analysis was calcu-
lated using the Mann–Whitney test.
Results
A collagen peptide library generated for systematic
epitope mapping of collagen type II
The human CII expression constructs used in this analysis
were based on the work of Engel and coworkers [17,18]
and the preparation and purification is further explained
in Additional file 1. In total, 70 recombinant human CII
(rCII) constructs were generated covering the entire
triple-helical domain of CII and the N-terminal collagen-
like sequence of human CII (Figure 1A). There are several
epitopes that have been discovered in CIA in mice and
these are marked in Figure 1A. C1, U1, and J1 are the
most studied epitopes, and antibodies specific for these
epitopes induce arthritis in mice [5-8,19,20]. Following ex-
pression and purification, the rCII peptides were analyzed
by sodium dodecyl sulfate polyacrylamide gel electropho-
resis, where each peptide band corresponded to the calcu-
lated mass of the triple-helical CII peptides (~25 kDa)
(Figure 1B). We confirmed that our monoclonal anti-
bodies were conformation dependent; that is, they were
restricted to binding the triple-helical CII epitopes in the
triple-helical state only, and bound to the rCII peptides
containing their specific epitope (Figure 1C). We could
also show that antibody binding to the rCII peptides was
completely abolished upon heat denaturation of the pep-
tides (Figure 1D).
Identification of several new collagen type II epitopes and
epitope spreading in arthritic mice
To follow the CII-specific antibody response throughout
different disease phases we used a mouse strain in which
CIA persists chronically, with a relapsing joint inflamma-
tion, for over 200 days (Figure 2A) [21]. Arthritis develop-
ment was monitored and sera were collected at three time
points (days 35, 80 and 210). The antibody reactivity of
the collected sera to the generated rCII peptide library
identified 10 rCII peptides that were frequently recog-
nized, and antibody specificity differed between the dif-
ferent disease phases (Figure 2A,B). Few rCII peptides
were recognized at disease onset (Figure 2C), whereas the
number of recognized epitopes dramatically increased
around early-chronic arthritis (Figure 2D) and slightly de-
creased in the late-chronic phase (Figure 2E). The rCII
Figure 1 Generation of a recombinant collagen type II peptide library. (A) Amino acid sequences of the inserted collagen type II (CII)
sequences into the GPP-Foldon scaffold and the corresponding peptide numbers (1 to 71). Underlined letters correspond to known B-cell and T-cell
epitopes followed with their names in brackets. The control peptide (rCII-71) lacks the CII insert but includes the Foldon trimerization domain and
GPP10. (B) Sodium dodecyl sulfate polyacrylamide gel electrophoresis showing protein bands at 25 kDa for all 71 rCII peptides. (C) Enzyme-linked
immunosorbent assay confirming monoclonal antibody recognition to four of the immunodominant rCII peptides (122:41 specific for rCII-13, CIIC1
specific for rCII-28, the UL1 antibody specific for rCII-37, M2139 recognizing rCII-41) and testing of the monoclonal antibody mix to the control peptide
rCII-71. (D) Monoclonal antibody CIIC1 binds to triple-helical but not heat-denatured rCII-28 peptides and rat CII. rCII, recombinant collagen type II.
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related rCII-28, rCII-37, and rCII041, which harbor the
major CII epitopes C1, U1, and J1. To investigate the
epitope-specific response to that of another arthritis
model we followed acute CIA in B10.Q male mice and
collected sera at day 50 for CII-specific analysis (Figure 2F).
Also here, during the established disease (Figure 2G) the
major CII epitopes C1, U1, and J1 were prominent to-
gether with several other both earlier identified and new
CII epitopes.
Antibody responses to C1, U1, and J1 are prominent in
two monkey species with CIA
To make comparative analyses in nonhuman primates we
selected two species, the rhesus macaque (M. mulatta)
and the common marmoset (C. jacchus). These developed
CIA after immunization with chicken-derived CII [13,22].
The arthritic nonhuman primates had high serum anti-
body responses towards rat CII, and sera from all 22
rhesus monkeys responded strongly to the major epitopes
C1 and U1 (Figure 3A). Sera from the majority of rhesus
monkeys (16 out of 22 samples) showed a high responsealso towards epitope J1. In contrast, sera from the common
marmosets displayed a broader variation in responses
against the two major epitopes C1 and U1, with more nega-
tive samples (Figure 3B). Positive responses to J1 were only
detected in three out of the 18 common marmosets.
High frequencies of antibodies to major collagen type II
epitopes were observed in RA serum and synovial fluid
samples
For analyzing the response in RA we used a previously
described cohort of established RA with both sera and
SF from the same patients [11], using an approach where
small CII triple-helical peptides of C1, U1, and J1 were
synthesized according to a protocol described by Grab
and colleagues [23]. We found that the antibody levels
against all three CII epitopes were higher in RA patients
compared with healthy controls, and the SF patient sam-
ples had higher titers than the paired serum samples
(Figure 3C,D). In addition, the frequency of patients
positive for the C1 and U1 epitopes in SF also increased
in comparison with sera: 23% versus 13% and 77% versus
47% for C1 and U1, respectively.
Figure 2 Specific antibody responses to recombinant collagen type II peptides in chronic and acute collagen-induced arthritis. (A) Chronic
arthritis in male mice from B10.Q × (BALB/c × B10.Q) N2 mice (n = 10). Clinical arthritis is denoted on the right y axis: straight lines, mean arthritis
score; dashed grey lines, mean + standard error the mean. Scoring of the mice was performed until day 201. The left y axis shows percent
responders to the overlapping recombinant collagen type (rCII) peptides in sera from chronic collagen-induced arthritis (CIA) mice at day 35
(onset), day 80 (early-chronic disease), and day 210 (late-chronic disease). (B) rCII peptides detected in ≥50% of the mice are included. (C), (D),
(E) Autoantibody recognition of rCII peptides in chronic CIA: dotted lines, cutoff calculated as the mean ± three standard deviations of naïve mice.
Numbers above the bars correspond to the rCII peptides in the library followed by the epitope name in brackets for B-cell epitopes identified
earlier. (F) CIA development in B10.Q male mice depicted as the mean arthritis score + standard error of the mean. (G) Sera from the acute CIA
mice, collected on day 50, were also tested for specificity to the rCII peptides.
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anti-citrullinated protein antibody response
To investigate whether the anti-CII antibodies define a
different subset of RA we used earlier data on the same
cohort [11] to correlate with the ACPA response. As
summarized in Table 1, all anti-CII antibodies show low
r values for correlation with cyclic citrullinated peptide(CCP), either in serum or SF. In comparison, antibodies
against the triple-helical C1 peptide citrullinated at both
arginine positions (that is, CitC1) positively correlate
with CCP in serum and SF (r = 0.655 and r = 0.643
respectively). Furthermore, in contrast to ACPA that are
confined to the CCP-positive RA subset, anti-CII anti-
bodies were found in both the CCP-positive and CCP-
Figure 3 Epitope-specific response in human rheumatoid arthritis and nonhuman primate species. (A), (B) Antibody responses to the
major collagen type II (CII) epitopes and to entire triple-helical rat CII in nonhuman primates (rhesus monkeys and common marmosets). The serum
dilution required for each individual to reach the cutoff absorbance value was calculated and is depicted on the y axis. All animals with antibody titers
below the detection limit were assigned a value of 1. (C) Antibody responses to major CII epitopes in sera from rheumatoid arthritis (RA) patients and
healthy control (HC) subjects. All individuals with antibody titers below the detection limit for positivity were assigned a value of 0.1. Each data point
represents one individual: dotted lines, cutoff value for positivity; horizontal red lines, median. (D) Antibody responses to major CII epitopes in sera and
synovial fluid (SF) from RA patients. After normalization based on the values for total IgG, the levels of anti-C1, anti-U1, and anti-J1 antibodies were
determined in paired samples of serum and SF from 290 RA patients. AU, arbitrary units. *P < 0.05, ***P < 0.001. Values are the mean ± standard error of
the mean.
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patients have anti-CitC1 antibodies in sera, 13% have
antibodies towards C1 and 38% towards U1. In SF 5% of
the CCP-negative patients have antibodies against CitC1,
whereas 13% and 63% have antibodies against C1 and
U1, respectively. The distribution of anti-CII antibodiesin these two subsets is further illustrated in Figure S1A,
B in Additional file 2.
We further examined whether CII antibodies follow
ACPA association with HLA-SE, in particular with HLA-
DRB1*04. We therefore divided our patients into three
different groups based on the identity of their SE alleles:
Table 1 Correlation and frequencies between collagen type II epitopes and CCP
Collagen type II epitope Correlation with CCP (r) Frequency in sera (%) Frequency in synovial fluid (%)
Serum Fluid CCP– CCP+ CCP– CCP+
C1 0.076 0.211 12.5 12.9 13.2 27.1
J1 0.012 0.130 8.8 5.7 7.7 5.5
U1 0.153 0.395 37.5 50.5 62.6 82.9
CitC1 0.655 0.643 6.2 53.8 5.5 49.7
CCP, cyclic citrullinated peptide.
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tients carrying one or two copies of DRB1*01 alleles
(n = 50, DR*01), and patients carrying one or two copies
of DRB1*04 alleles (n = 127, DR*04). To better stratify the
analysis, patients carrying both the DRB1*01 allele and the
DRB1*04 allele (n = 40) were excluded from this analysis. In
contrast to ACPA levels that strongly associate with HLA-
DRB1*04, the CII examined antibody level association was
less pronounced with HLA-DRB1*04 or other SE alleles
(Table 2; Figure S2A,B,C,D,E,F in Additional file 3).
Discussion
In this study we demonstrate that anti-CII antibodies, in
particular antibodies directed to the major epitope U1, are
frequent and present at the site of inflammation in RA. A
significant higher antibody response against the U1 epi-
tope was observed in SF (77%) compared with levels in
sera (47%), supporting the notion of an increased immune
response to locally released CII in the joints. This suggests
that anti-CII antibodies appear around the clinical onset
and are likely to play a role in the disease process. Anti-
bodies to the investigated three CII epitopes are all shown
to be highly arthritogenic in mouse models of RA and one
of the first steps observed in the joint pathology is
antibody-induced destabilization of cartilage [8]. This
observation could open up this tissue for a subsequent
inflammatory attack.
We observed a higher prevalence of CII-specific anti-
bodies directed against U1 using our triple-helical pep-
tides compared with previous studies using CII as antigen
[2,4]. There are several possible explanations for the
higher frequency of CII-positive patients when using
defined triple-helical peptides as compared with CII iso-
lated from cartilage. Firstly, semi-purified CII derived from
tissue is in complex with other matrix proteins, and also
with pepsin used for tissue extraction. These conta-
minants could very probably block potential CII epitopes.
Secondly, crosslinking with fibrinogen or denaturation of
CII in vitro is likely to disturb assays using semi-purified
CII. Thirdly, the smaller triple-helical CII epitopes are
coated on enzyme-linked immunosorbent assay plates at
higher molar densities than the large CII protein, resulting
in capture of antibodies with lower affinity.Using our assay with defined triple-helical CII epitopes
possibly allowed detection of antibodies with lower affi-
nity, and this may have a large effect on the detection rate.
Importantly, the anti-CII antibody response in mice, even
antibodies that are pathogenic, are to a large extent germ-
line encoded and thereby lack somatic mutated, generated
affinity maturation [6,7,24,25]. The observed anti-CII anti-
body response was not confined to the CCP-positive
subset of RA and did not significantly associate with spe-
cific HLA-DR alleles. The lack of HLA-DR association
could, however, be due to low statistical power and be-
cause we used a cohort with more established RA, since
earlier investigations into early RA have suggested a weak
association with DRB1*0401 [26,27].
Despite the genetic differences between rodents, mon-
keys, and humans and the fact that the experimental
arthritis was induced through immunization with CII in
the various species leading to strong anti-CII antibody
responses, the fine specificity of the major epitopes was
still largely conserved. The only exception was the lack of
response to the J1 epitope in the common marmoset. This
lack is in fact similar to the mouse in which the response
to J1 is strain specific [28]. Interestingly, the heterogeneity
in the mouse has been mapped to the variable heavy chain
locus, indicating that constraints of the binding structures
lead to restrictions in using allele-specific V genes [7]. The
analysis of the triple-helical peptide CII library showed
that numerous epitopes could be targeted by autoanti-
bodies and responses against different CII epitopes vary at
different stages of the disease. The generated CII peptide
library revealed that the three more thoroughly investi-
gated major CII epitopes are present in both acute and
chronic stages of arthritis. The binding site of a CII-
binding antibody is often the site for binding of matrix
proteins (reviewed in [10]), which could explain why the
epitope specificity of the antibodies is important for their
pathogenicity. CII provides numerous epitopes that are
recognized by antibodies in RA but there are also other
cartilage protein epitopes to be detected. This leads to the
possibility that cartilage is frequently recognized in RA
and that these antibodies could play an important role in
the disease. Assays to detect such antibodies would there-
fore provide valuable information, in particular to predict
Table 2 Odds ratio for the association of antibody-positive patients within the different HLA-DRB1 groups
No SE (n = 47) HLA-DRB1*01 (n = 50) HLA-DRB1*04 (n = 127)
Antigen Frequency of
positive patients (%)
Frequency of
positive patients (%)
Odds ratio DR*01 vs. no SE Frequency of
positive patients (%)
Odds ratio DR*04 vs. no SE Odds ratio DR*04 vs. DR*01
C1 sera 14.9 16 1.088, 95% CI 0.3613 to 0.280 11.8 0.7653, 95% CI0.291 to 2.013 0.703, 95% CI 0.278 to 1.780
C1 SF 10.6 22 2.369, 95% CI 0.755 to 7.436 25.2 2.829, 95% CI 1.030 to 7.771 1.194, 95% CI 0.547 to 2.605
J1 sera 6.4 14 2.388, 95% CI 0.579 to 9.845 5.5 0.856, 95% CI 0.212 to 3.457 0.3583, 95% CI 0.119 to 1.081
J1 SF 6.4 8 1.275, 95% CI 0.361 to 3.280 7.1 1.119, 95% CI 0.289 to 4.324 0.469, 95% CI 0.164 to 1.336
U1 sera 42.6 38 0.827, 95% CI 0.367 to 1.865 48 1.227, 95% CI 0.624 to 2.413 1.483, 95% CI 0.759 to 2.898
U1 SF 68.1 82 2.135, 95% CI 0.828 to 5.506 76.4 1.516, 95% CI 0.7245 to 3.169 0.710, 95% CI 0.310 to 1.627
CitC1 sera 27.6 26 0.919, 95% CI 0.374 to 2.258 53 2.921, 95% CI 1.410 to 6.049 3.178, 95% CI 1.544 to 6.541
CitC1 SF 17 26 1.713, 95% CI 0.637 to 4.606 48.8 4.650, 95% CI 2.014 to 10.74 2.715, 95% CI 1.319 to 5.586
CI, confidence interval; SF, synovial fluid.
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section of the CII epitopes, and their citrullinated counter-
parts [29,30], could be of importance to understand the
pathogenic and regulatory pathways in RA.
Conclusions
Antibody responses against triple-helical CII epitopes
are common in RA, and the high antibody titers in SF
indicate that these are likely to originate from rheuma-
toid joints. However, there was no correlation with the
ACPA response. Importantly, the fine specificity of the
anti-CII response is largely conserved between RA in
humans and CIA in monkeys and rodents where the rec-
ognized epitopes have a major pathogenic role. In con-
clusion, our results suggest that anti-CII antibodies are
likely to reflect a pathway other than ACPA and may
both contribute to, as well as be the consequence of,
local joint inflammation.
Additional files
Additional file 1: is a description of supplementary materials and
methods for CII peptide design, expression and purification of
recombinant CII peptides, and antibody measurements in mice sera
with recombinant CII peptides, rhesus monkeys and common
marmosets.
Additional file 2: is Figure S1A and S1B showing the distribution of
anti-CII antibodies in sera and in synovial fluid of CCP-positive and
CCP-negative RA subsets.
Additional file 3: is Figure S2A,B,C,D,E,F showing the association
between CII antibodies and HLA-SE alleles, in particular HLA-DRB1*04.
The patients were divided into three different groups based on the identity
of their SE alleles: those who do not carry the SE alleles (n = 47, −/−),
patients carrying one or two copies of DRB1*01 alleles (n = 50, DR*01), and
patients carrying one or two copies of DRB1*04 alleles (n = 127,DR*04). To
better stratify the analysis, patients carrying both the DRB1*01 allele and the
DRB1*04 allele (n = 40) were excluded from this analysis. AU, arbitrary units.
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